F
Faeth Therapeutics
Faeth Therapeutics, Inc. is customizing diets for oncology patients, based on their tumor genomics
About Faeth Therapeutics
Faeth Therapeutics is a pioneering startup in the healthcare sector, specifically in the field of cancer treatment. The company operates in the market of cancer therapeutics, serving patients suffering from various types of tumors. Faeth's unique approach involves the use of metabolic data to develop safer and more effective therapies.
The company's proprietary MetabOS platform is a groundbreaking innovation that offers new insights into drug-nutrient interactions across all tumor types. This platform is used to optimize the metabolic process through diet, thereby introducing a novel method of treating cancer. Faeth pairs its anti-cancer drugs with precision diets or other metabolism-focused drugs to enhance the overall treatment outcomes and reduce toxicity.
Faeth's business model is centered around its therapeutic programs that combine anti-cancer drugs with precision diets. These diets are specifically designed to increase the efficacy of the drugs and decrease their adverse effects. This makes Faeth's treatments more potent against tumors and easier for patients to tolerate. The company generates revenue by offering these unique therapeutic programs to patients.
Faeth also encourages patients to participate in clinical trials, which not only helps in the development and refinement of their therapies but also provides patients with access to potentially life-saving treatments.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2019
- Headquarters
- San Francisco, United States
- Employees
- 29
- Open positions
- 22
- Dealroom signal
- 76.5/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Chronic Disease, Spinout, Digital Therapeutics, Biotech and Pharma, DT and LS, science-based
- Business model
- SaaS
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Feb 2026 | $0 | — | Sensei Biotherapeutics | ↗ |
| LATE VCOther financing | Oct 2025 | $25M | $235M | Cantos Ventures · Avicella Capital · Khosla Ventures · B Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Faeth Therapeutics is 5.6K monthly website visits, up 154.5% over the last three months. Faeth Therapeutics's team grew 3.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Faeth Therapeutics in the San Francisco ecosystem
The Faeth Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Future Ventures
Unshackled
AgFunder
Cantos Ventures
S2G Investments
KdT Ventures
Digitalis Ventures
Series A1 investor entered at this stage
Series B and later3 investors entered at this stage
- ACAvicella Capital
B Capital
THO SeedFund
Other known investors3 additional known investors
Cornell Tech
Cornell University
Sensei Biotherapeutics
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Faeth Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Faeth Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











